ABEO ABEONA THERAPEUTICS INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 318306 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-175.9%
TTM EPS YoY-189.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin65.1%
Operating margin-186.1%
Net margin-160.3%
FCF margin-170.1%
EBITDA margin-178.5%
Returns
ROE-42.1%
ROA-31.0%
ROIC (approx.)-59.9%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets26.8%
Debt / equity0.19x
Current ratio5.69x
Interest coverage-24.47x
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue7.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $13.49M | $11.38M | $8.72M | $5.42M | $0 | $400,000 | — | — |
| Cost of revenue | $5.71M | $4.18M | $2.70M | $1.04M | $488,000 | — | — | — |
| Gross profit | $7.78M | $7.20M | $6.02M | $4.38M | -$488,000 | — | — | — |
| R&D expense | $3.67M | $5.02M | $9.55M | $6.71M | $4.22M | $5.94M | $9.94M | $8.99M |
| SG&A expense | $17.11M | $15.84M | $19.50M | $18.78M | $19.31M | $17.15M | $9.79M | $7.68M |
| Operating income | -$13.00M | -$13.65M | -$23.03M | -$22.91M | -$24.02M | -$22.79M | -$19.73M | -$16.67M |
| Interest expense | $557,000 | $696,000 | $830,000 | $884,000 | $901,000 | $957,000 | $998,000 | $1.08M |
| Pretax income | -$4.79M | -$20.19M | -$17.07M | -$20.68M | -$20.36M | $124.34M | -$12.03M | -$9.29M |
| Income tax | $18,000 | $0 | $2,000 | -$215,000 | -$15.20M | $15.51M | — | — |
| Net income | -$4.81M | -$20.19M | -$17.07M | -$20.46M | -$5.16M | $108.83M | -$12.03M | -$9.29M |
| EBITDA | -$12.30M | -$12.95M | -$22.34M | -$22.05M | -$23.42M | -$22.19M | -$19.19M | -$16.13M |
| EPS (basic) | -0.08 | -0.35 | -0.30 | — | -0.10 | 2.07 | -0.24 | — |
| EPS (diluted) | -0.08 | -0.35 | -0.30 | — | -0.10 | 1.71 | -0.24 | — |
| Weighted avg. shares (diluted) | 57.86M | 57.05M | 56.62M | — | 54.24M | 66.64M | 49.78M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $66.28M | $56.23M | $61.37M | $78.44M | $82.88M | $163.53M | $15.94M | $23.36M |
| Short-term investments | $68.66M | $90.60M | $106.90M | $112.97M | $124.23M | $61.98M | $68.22M | $74.36M |
| Receivables | $15.73M | $9.39M | $6.20M | $6.15M | — | — | — | — |
| Inventory | $4.66M | $5.92M | $6.05M | $5.49M | $4.85M | $2.69M | — | — |
| Current assets | $157.72M | $164.58M | $182.99M | $204.91M | $216.13M | $232.26M | $88.12M | $100.85M |
| PP&E, net | $9.49M | $10.15M | $10.56M | $9.92M | $10.34M | $9.49M | $6.95M | $4.43M |
| Total assets | $171.92M | $179.51M | $198.49M | $219.57M | $231.09M | $246.23M | $99.36M | $108.93M |
| Current liabilities | $27.71M | $24.81M | $31.05M | $29.57M | $22.18M | $34.52M | $17.98M | $16.59M |
| Short-term debt | $11.85M | $13.33M | $13.33M | $12.22M | $8.89M | $5.56M | $8.15M | $5.93M |
| Long-term debt | $11.85M | $1.66M | $4.75M | $7.81M | $10.86M | $14.01M | $11.14M | $13.04M |
| Total debt | $23.69M | $14.99M | $18.09M | $20.04M | $19.75M | $19.56M | $19.29M | $18.96M |
| Total liabilities | $46.05M | $51.45M | $53.55M | $60.35M | $59.86M | $82.66M | $57.97M | $64.90M |
| Shareholders' equity | $125.88M | $128.06M | $144.94M | $159.22M | $171.23M | $163.58M | $41.40M | $44.03M |
| Net debt | -$42.59M | -$41.24M | -$43.29M | -$58.40M | -$63.13M | -$143.97M | $3.35M | -$4.39M |
| Shares outstanding | 57.17M | 57.23M | 56.87M | 55.04M | 52.40M | 51.25M | 48.95M | 45.64M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.31M | -$17.50M | -$19.80M | -$17.95M | -$21.19M | -$18.78M | -$18.40M | -$16.56M |
| Capital expenditure | $219,000 | $479,000 | $935,000 | $1.15M | $2.52M | $2.90M | $1.40M | $606,000 |
| Free cash flow | -$8.53M | -$17.98M | -$20.74M | -$19.11M | -$23.71M | -$21.68M | -$19.80M | -$17.16M |
| Investing cash flow | $21.70M | $15.69M | $4.96M | $9.55M | -$64.63M | $155.89M | $4.21M | $18.88M |
| Financing cash flow | -$3.34M | -$3.33M | -$2.22M | $3.61M | $5.16M | $10.49M | $6.77M | $5.31M |
| Depreciation & amortization | $700,000 | $700,000 | $690,000 | $863,000 | $600,000 | $600,000 | $534,000 | $539,000 |
| Stock-based compensation | $2.79M | $3.37M | $2.96M | $2.56M | $2.69M | $2.83M | $2.70M | $1.96M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.